Skip to content Skip to sidebar Skip to footer
Spotlight_Barbara Albientz
Reuters Pharma 2025: Post-Conference Talks Featuring Barbara Albientz
Barbara Albientz, Chief Commercialization Officer, Helvion Pharmaceuticals, joins PharmaShots’ Managing Editor Himanshu Sehgal for a riveting dialogue exchange. Barbara shares her experience from the recently held Reuters Events Pharma 2025, where she joined as an affirmative team member for the debate Reality Check: Is Omnichannel Actually Working?Barbara believes AI will be crucial in segmenting…
Regulus Therapeutics
Novartis to Acquire Regulus Therapeutics for ~$1.7B
Shots:Novartis to acquire Regulus Therapeutics incl. its lead asset, farabursen via its wholly owned subsidiary, which will merge with Regulus upon closing, resulting in Regulus becoming an indirect wholly owned subsidiary of NovartisAs per the deal, Regulus will get ~$0.8B upfront, with shareholders receiving $7/share in cash, & ~$0.9B upon achievement of a…
Teleflex
Teleflex’s QuikClot Control+ Hemostatic Device Receives the US FDA’s 510(k) Clearance to Temporary Control All Bleeding Grades
Shots:The US FDA has granted 510(k) clearance for label expansion of QuikClot Control+ Hemostatic Device to control all grades of internal & external bleedingLabel expansion was supported by real-world evidence from an observational study evaluating QuikClot Control+ in 603 US emergency, trauma, & surgical pts across all bleeding grades & varied anatomical sites…
Bayar
Bayer Reports Post-Hoc Data from P-III (ARANOTE) Trial of Nubeqa to Treat Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Shots:Bayer has reported post-hoc analyses from P-III (ARANOTE) trial assessing Nubeqa (darolutamide; 600mg, BID) + androgen deprivation therapy (ADT) (n=446) vs PBO + ADT (n=223) in mHSPC pts (N=669)Post-hoc analyses showed that 42.6% pts achieved ultra-low PSA levels (<0.02ng/mL) vs 7.8% pts on PBO & this response was associated with prolonged rPFS, delayed…